85259-47-8

Usage

Uses

Used in Pharmaceutical Industry:
2-Pyridinecarboxaldehyde, 6-ethoxy(9CI) is used as an intermediate in the manufacturing of pyridyl-ethanol and pyridyl-ethenol derivatives, which are key components in the development of antihistamines, quinolone drugs, and other pharmaceuticals. Its role in the synthesis of these compounds contributes to the treatment and management of various health conditions.
Used in Agrochemical Industry:
As a building block in the synthesis of agrochemicals, 2-Pyridinecarboxaldehyde, 6-ethoxy(9CI) plays a crucial role in the development of products that protect crops and enhance agricultural productivity.
Used in Fragrance and Flavor Industry:
Due to its pleasant odor, 2-Pyridinecarboxaldehyde, 6-ethoxy(9CI) is utilized in the synthesis of fragrances and flavors, adding to the sensory experience of various consumer products.

Upstream product

• 19621-92-2 6-Hydroxypicolinic acid 
• 890655-74-0 ethyl 6-ethoxypicolinate 
• 890655-75-1 (6-ethoxypyridin-2-yl)methanol 

Relevant academic research and scientific papers

SUBSTITUENT-INCLUDING UREA COMPOUND

An object of the present invention is to provide a compound that has a specific chemical structure having an activation effect on SIRT6 and is useful as an active component for preventing and treating inflammatory diseases. The present invention relates to a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof. (Each symbol in Formula (1) has the same definition as that described in the specification.)

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY

This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol APLNR). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition. Non-limiting examples of such diseases, disorders, or conditions include: (i) cardiovascular disease; (ii) metabolic disorders; (iii) diseases, disorders, and conditions associated with vascular pathology; and (iv) organ failure; (v) diseases, disorders, and conditions associated with infections (e.g., microbial infections); and (vi) diseases, disorders, or conditions that are sequela or comorbid with any of the foregoing or any disclosed herein. More particular non-limiting examples of such diseases, disorders, or conditions include pulmonary hypertension (e.g., PAH); heart failure; type II diabetes; renal failure; sepsis; and systemic hypertension.

NOVEL PYRROLO [3, 2-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY

There are disclosed novel compounds of formula (I) wherein R1, R12, L, X and Y are as defined in the specification, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing